New lung cancer indication for Tarceva

by
In the SATURN trial in 889 patients with locally advanced or metastatic NSCLC whose disease had not progressed after 4 cycles of platinum-based doublet chemotherapy, mean progression-free survival was 22.4 weeks in the erlotinib group compared with 1
In the SATURN trial in 889 patients with locally advanced or metastatic NSCLC whose disease had not progressed after 4 cycles of platinum-based doublet chemotherapy, mean progression-free survival was 22.4 weeks in the erlotinib group compared with 1

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package